Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.

Balakrishnan A, Rajan A, Salter AI, Kosasih PL, Wu Q, Voutsinas J, Jensen MC, Pl├╝ckthun A, Riddell SR.

Clin Cancer Res. 2019 Sep 23. doi: 10.1158/1078-0432.CCR-19-1479. [Epub ahead of print]

PMID:
31548346
2.

Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues.

Balakrishnan A, Goodpaster T, Randolph-Habecker J, Hoffstrom BG, Jalikis FG, Koch LK, Berger C, Kosasih PL, Rajan A, Sommermeyer D, Porter PL, Riddell SR.

Clin Cancer Res. 2017 Jun 15;23(12):3061-3071. doi: 10.1158/1078-0432.CCR-16-2083. Epub 2016 Nov 16.

3.

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo.

Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, Riddell SR.

Leukemia. 2016 Feb;30(2):492-500. doi: 10.1038/leu.2015.247. Epub 2015 Sep 15.

4.

Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.

Berger C, Sommermeyer D, Hudecek M, Berger M, Balakrishnan A, Paszkiewicz PJ, Kosasih PL, Rader C, Riddell SR.

Cancer Immunol Res. 2015 Feb;3(2):206-16. doi: 10.1158/2326-6066.CIR-14-0163. Epub 2014 Oct 29.

5.

The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.

Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, Jensen MC, Riddell SR.

Cancer Immunol Res. 2015 Feb;3(2):125-35. doi: 10.1158/2326-6066.CIR-14-0127. Epub 2014 Sep 11.

6.

Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.

Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, Riddell SR.

Clin Cancer Res. 2013 Jun 15;19(12):3153-64. doi: 10.1158/1078-0432.CCR-13-0330. Epub 2013 Apr 25.

Supplemental Content

Loading ...
Support Center